The American Journal of Managed Care

Choosing Wisely: Insights from an MAIC and eXalt3

Panelists discuss how matching-adjusted indirect comparisons (MAIC) of ALK inhibitors and the FDA approval of ensartinib in December 2024 influence frontline treatment selection for ALK+ non–small ...
The American Journal of Managed Care

MAIC Analyses and Bispecific Therapies: Guiding Treatment Decisions in B-Cell Lymphomas

Panelists discuss how comparative data from matching-adjusted indirect comparison (MAIC) analyses guide treatment decisions between bispecific therapies and the insights from MAIC results comparing ...
ascopubs.org

Matching-adjusted indirect comparison (MAIC) of mobocertinib versus amivantamab in patients with non–small cell lung cancer (NSCLC) with EGFR exon 20 insertions (ex20ins).

Abbreviations: ESS=effective sample size; mos=months; NE: not estimable. [1] Park K, et al. JCO 2021;39(30):3391-3402. a estimated using reconstructed patient-level data from swimmer and survival ...
ascopubs.org

Matching-adjusted indirect comparison (MAIC) of teclistamab (tec) versus selinexor-dexamethasone (sel-dex) for the treatment of patients (pts) with triple-class exposed (TCE ...

COVID-19 impact on multiple myeloma prescribing patterns. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract does not include a full text component.